This study aims to recruit 20 participants who will take the combination anti-HIV drug
tenofovir+emtricitabine (TDF/FTC) at specified times. Participants will then provide biologic
samples for the measurement of anti-retroviral drug concentrations in various body
compartment sites. Participants will be involved in the study for up to 24 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Emory University
Collaborator:
Centers for Disease Control and Prevention
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination